Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

Hugo, Willy, Zaretsky, Jesse M., Sun, Lu, Song, Chunying, Moreno, Blanca Homet, Hu-Lieskovan, Siwen, Berent-Maoz, Beata, Pang, Jia, Chmielowski, Bartosz, Cherry, Grace, Seja, Elizabeth, Lomeli, Shirley, Kong, Xiangju, Kelley, Mark C., Sosman, Jeffrey A., Johnson, Douglas B., Ribas, Antoni, Lo, Roger S.·2016·Cell
DOI 10.1016/j.cell.2016.02.065

Cited by (1,009)

Items 601–700 of 1,009

  1. Alterations of DNA damage repair in cancer: from mechanisms to applications
    Minlin Jiang, Keyi Jia, Lei Wang, Wei Li, Bin Chen, Yu Liu, Hao Wang, Sha Zhao, Yayi He, Caicun Zhou · 2020 · Annals of Translational Medicine
  2. Modulating tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors: A TAM-pting approach
    Ali N. Chamseddine, Tarek Assi, Olivier Mir, Salem Chouaı̈b · 2021 · Pharmacology & Therapeutics
  3. S100A9-CXCL12 activation in BRCA1-mutant breast cancer promotes an immunosuppressive microenvironment associated with resistance to immunotherapy
    Jianjie Li, Xiaodong Shu, Jun Xu, Sek Man Su, Un In Chan, Lihua Mo, Jianlin Liu, Xin Zhang, Ragini Adhav, Qiang Chen et al. · 2022 · Nature Communications
  4. The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies
    Mika L. Persson, Alicia M. Douglas, Frank Alvaro, Pouya Faridi, Martin R. Larsen, Marta María Alonso, Nicholas Alexander Vitanza, Matthew D. Dun · 2022 · Neuro-Oncology
  5. Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma
    Katie Marie Campbell, Meelad Amouzgar, Shannon M. Pfeiffer, Timothy R. Howes, Egmidio Medina, Michael Travers, Gabriela Steiner, Jeffrey S. Weber, Jedd D. Wolchok, James Larkin et al. · 2023 · Cancer Cell
  6. Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma
    Kathryn Eby Beckermann, Pradeep C. Jolly, Ju Young Kim, Jennifer Bordeaux, Igor J. Puzanov, W. Kimryn Rathmell, Douglas Buckner Johnson · 2017 · Journal for ImmunoTherapy of Cancer
  7. The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy
    Shi, Congqi, Qin, Kaiyu, Lin, Anqi, Jiang, Aimin, Cheng, Quan, Liu, Zaoqu, Zhang, Jian, Luo, Peng · 2022 · Journal of Experimental & Clinical Cancer Research
  8. Multilevel genomics of colorectal cancers with microsatellite instability—clinical impact of JAK1 mutations and consensus molecular subtype 1
    Anita Sveen, Bjarne Johannessen, Torstein Tengs, Stine Aske Danielsen, Ina Andrassy Eilertsen, Guro Elisabeth Lind, Kaja C. G. Berg, Edward Leithe, Leonardo A. Meza‐Zepeda, Enric Domingo et al. · 2017 · Genome Medicine
  9. HLA class I loss and PD-L1 expression in lung cancer: impact on T-cell infiltration and immune escape
    Francisco Perea, Abel Sánchez‐Palencia, Mercedes Gómez‐Morales, Mónica Bernal, Ángel Concha, Míguela Méndez García, Amanda Rocío González Ramírez, Martin Kerick, Javier J. Martin, Federico Garrido et al. · 2017 · Oncotarget
  10. Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma
    Thomas B. Powles, Robert John Motzer, Bernard J. Escudier, Sumanta Kumar Pal, Christian Kollmannsberger, Joanna Pikiel, Howard Gurney, Sun Young Rha, Se Hoon Park, Poul Flemming Geertsen et al. · 2018 · British Journal of Cancer
  11. Integrating tumor hypoxic stress in novel and more adaptable strategies for cancer immunotherapy
    Raefa Abou Khouzam, Goutham Hassan Venkatesh, Rania Faouzi Zaarour, Ali N. Chamseddine, Amirtharaj Francis, Stéphanie Buart, Stéphane Terry, Salem Chouaı̈b · 2020 · Seminars in Cancer Biology
  12. Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis
    Jiahang Mo, Xiao Hu, Lihu Gu, Bangsheng Chen, Parikshit Asutosh Khadaroo, Zefeng Shen, Lei Dong, Yuqi Lv, Marylin Nyaradzo Chitumba, Jiequan Liu · 2020 · World Journal of Surgical Oncology
  13. Mutations in the IFNγ-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment
    Tan-Trieu Nguyen, LeeAnn Ramsay, Mozhdeh Ahanfeshar-Adams, Mathieu Lajoie, Dirk Schadendorf, Tommy Alain, Ian R. Watson · 2021 · Clinical Cancer Research
  14. CD73 in small extracellular vesicles derived from HNSCC defines tumour‐associated immunosuppression mediated by macrophages in the microenvironment
    Tingwei Lu, Zhen Zhang, Jianjun Zhang, Xinhua Pan, Xueqin Zhu, Xu Wang, Zhihui Li, Min Ruan, Huasheng Li, Wantao Chen et al. · 2022 · Journal of Extracellular Vesicles
  15. When Genome Maintenance Goes Badly Awry
    Elizabeth M. Kass, Mary Ellen Moynahan, Maria Jasin · 2016 · Molecular Cell
  16. Combining PARP Inhibition, Radiation, and Immunotherapy: A Possible Strategy to Improve the Treatment of Cancer?
    Mathieu Césaire, Juliette Thariat, Serge M. Candéias, Dinu Stefan, Yannick Saintigny, François Chevalier · 2018 · International Journal of Molecular Sciences
  17. The nuclear oncoprotein Fra-1: a transcription factor knocking on therapeutic applications’ door
    Francesco Talotta, Laura Casalino, Pasquale Verde · 2020 · Oncogene
  18. The emerging role of Wnt5a in the promotion of a pro-inflammatory and immunosuppressive tumor microenvironment
    Pablo Lopez‐Bergami, Gastón Barbero · 2020 · Cancer and Metastasis Reviews
  19. Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma
    Valsamo Anagnostou, Daniel C. Bruhm, Noushin Niknafs, James Robert White, Xiaoshan M. Shao, John-William Sidhom, Julie E. Stein, Hua‐Ling Tsai, Hao Wang, Zineb Belcaid et al. · 2020 · Cell Reports Medicine
  20. Gene fusion neoantigens: Emerging targets for cancer immunotherapy
    Yue Wang, Tao Shi, Xueru Song, Baorui Liu, Jia Wei · 2021 · Cancer Letters
  21. Leveraging big data of immune checkpoint blockade response identifies novel potential targets
    Yacine Barèche, Deirdre Kelly, Farnoosh Abbas Aghababazadeh, M. Nakano, Parinaz Nasr Esfahani, Douglas Tkachuk, H. Mohammad, Robert M. Samstein, Chung‐Han Lee, Luc G.T. Morris et al. · 2022 · Annals of Oncology
  22. Advances in immunotherapy for the treatment of glioblastoma
    Amanda Tivnan, Tatjana Heilinger, Ed C. Lavelle, Jochen H.M. Prehn · 2016 · Journal of Neuro-Oncology
  23. Sensitive Detection and Analysis of Neoantigen-Specific T Cell Populations from Tumors and Blood
    Songming Peng, Jesse Meir Zaretsky, Alphonsus H. C. Ng, William Chour, Michael T. Bethune, Jongchan Choi, Alice C Hsu, Elizabeth A. Holman, Xiaozhe Ding, Katherine L. Guo et al. · 2019 · Cell Reports
  24. Systematic characterization of mutations altering protein degradation in human cancers
    Collin J. Tokheim, Xiaoqing Wang, Richard T. Timms, Boning Zhang, Elijah L. Mena, Binbin Wang, Cynthia Chen, Jun Ge, Jun Chu, Wubing Zhang et al. · 2021 · Molecular Cell
  25. Pan‐Cancer Single‐Cell and Spatial‐Resolved Profiling Reveals the Immunosuppressive Role of APOE+ Macrophages in Immune Checkpoint Inhibitor Therapy
    Chuan Liu, Jindong Xie, Bo Lin, Weihong Tian, Yifan Wu, Xin Shan, Libing Hong, Xin Li, Lulu Liu, Yuzhi Jin et al. · 2024 · Advanced Science
  26. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma
    Elena De Mattia, Erika Cecchin, Michela Guardascione, Luisa Foltran, Tania Di Raimo, Francesco Angelini, Mario Rosario D'Andrea, Giuseppe Toffoli · 2019 · World Journal of Gastroenterology
  27. Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response
    Qingyang Xiao, André Nobre, Pilar Piñeiro, Miguel‐Ángel Berciano‐Guerrero, Emilio Alba, Manuel Cobo, Volker Martin Lauschke, Isabel Barragán · 2020 · Journal of Clinical Medicine
  28. Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-infiltrating lymphocytes
    Wantao Wu, Yihan Liu, Shan Zeng, Ying Han, Hong Shen · 2021 · Journal of Hematology & Oncology
  29. Transcriptional Mechanisms of Resistance to Anti–PD-1 Therapy
    Maria Libera Ascierto, Alvin P. Makohon-Moore, Evan J. Lipson, Janis Marie Taube, Tracee L. McMiller, Alan E. Berger, Jinshui Fan, Genevieve J. Kaunitz, Tricia R. Cottrell, Zachary A. Kohutek et al. · 2017 · Clinical Cancer Research
  30. Deep exploration of the immune infiltrate and outcome prediction in testicular cancer by quantitative multiplexed immunohistochemistry and gene expression profiling
    Siska, Peter J., Johnpulle, Romany A. N., Zhou, Alice, Bordeaux, Jennifer, Kim, Ju Young, Dabbas, Bashar, Dakappagari, Naveen, Rathmell, Jeffrey C., Rathmell, W. Kimryn, Morgans, Alicia K. et al. · 2017 · OncoImmunology
  31. PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression
    Michal Šmahel · 2017 · International Journal of Molecular Sciences
  32. Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy
    Yared Hailemichael, Amber N. Woods, Tihui Fu, Qiuming He, Michael C. Nielsen, Farah Hasan, Jason Roszik, Zhilan Xiao, Christina Vianden, Hiep Khong et al. · 2018 · Journal of Clinical Investigation
  33. Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade
    Stéphane Terry, Cécile Dalban, Nathalie C. Rioux-Leclercq, Julien Adam, Maxime Meylan, Stéphanie Buart, Antoine Bougoüin, Alexandra Lespagnol, Frédéric Dugay, Irelka Colina Moreno et al. · 2021 · Clinical Cancer Research
  34. Epithelial–Mesenchymal Plasticity in Tumor Immune Evasion
    Riley D. Z. Mullins, Ananya Pal, Thomas F. Barrett, Molly E. Heft Neal, Sidharth V. Puram · 2022 · Cancer Research
  35. Indicators of responsiveness to immune checkpoint inhibitors
    Bradley D. Shields, Fade Aziz Mahmoud, Erin M. Taylor, Stephanie D. Byrum, Deepanwita Sengupta, Brian S. Koss, Giulia Baldini, Seth C. Ransom, Kyle Cline, Samuel G. Mackintosh et al. · 2017 · Scientific Reports
  36. Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy
    Wen Cheng, Dian Fu, Feng Xu, Zhengyu Zhang · 2018 · Oncogenesis
  37. Predictive and on-treatment monitoring biomarkers in advanced melanoma: Moving toward personalized medicine
    Ahmad A. Tarhini, Ragini Reiney Kudchadkar · 2018 · Cancer Treatment Reviews
  38. A four-DNA methylation biomarker is a superior predictor of survival of patients with cutaneous melanoma
    Wenna Guo, Liucun Zhu, Rui Zhu, Qihan Chen, Qiang Wang, Jian‐Qun Chen · 2019 · eLife
  39. Tumor-Infiltrating Lymphocytes in the Checkpoint Inhibitor Era
    Gerald P. Linette, Beatriz M. Carreno · 2019 · Current Hematologic Malignancy Reports
  40. Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab
    Omid Hamid, Luciana Lorena Molinero, Christopher R. Bolen, Jeffrey Alan Sosman, Eva Muñoz‐Couselo, Harriet M. Kluger, David F. McDermott, John D. Powderly, Indrani Sarkar, Marcus D. Ballinger et al. · 2019 · Clinical Cancer Research
  41. MDM2, MDM4 and EGFR Amplifications and Hyperprogression in Metastatic Acral and Mucosal Melanoma
    Andrea Forschner, Franz-Joachim Hilke, Irina Bonzheim, Axel Gschwind, German M. Demidov, Teresa Maria Santos Amaral, Stephan Ossowski, Olaf Rieß, Christopher Schroeder, Peter Martus et al. · 2020 · Cancers
  42. Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers
    Zhihao Lü, Zhi Peng, Chang Xin Liu, Zhenghang Wang, Yakun Wang, Xi Jiao, Jian Li, Lin Shen · 2020 · The Innovation
  43. Covalent Organic Framework-Based Nanocomposite for Synergetic Photo-, Chemodynamic-, and Immunotherapies
    Sainan Liu, Ying Zhou, Chunling Hu, Lihan Cai, Maolin Pang · 2020 · ACS Applied Materials & Interfaces
  44. Comprehensive Analysis of Pyroptosis-Related Genes and Tumor Microenvironment Infiltration Characterization in Breast Cancer
    Jianbin Wu, Yuanyuan Zhu, Mingmin Luo, Lei Li · 2021 · Frontiers in Immunology
  45. Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types
    Răzvan Cristescu, Michael Nebozhyn, Chunsheng Zhang, Andrew V Albright, Julie Kobie, Lingkang Huang, Qing Zhao, Anran Wang, Hua Ma, Zhu Alexander Cao et al. · 2021 · Clinical Cancer Research
  46. Newly developed 3D in vitro models to study tumor–immune interaction
    Peiyuan Mu, Shujuan Zhou, Tao Lv, Fan Xia, Lijun Shen, Juefeng Wan, Yaqi Wang, Hui Zhang, Sanjun Cai, Junjie Peng et al. · 2023 · Journal of Experimental & Clinical Cancer Research
  47. Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas
    Yoko Tsukita, Naoya Fujino, Eisaku Miyauchi, Ryoko Saito, Fumiyoshi Fujishima, Koji Itakura, Yorihiko Kyogoku, Koji Okutomo, Mitsuhiro Yamada, Tatsuma Okazaki et al. · 2019 · Molecular Cancer
  48. Pan-cancer analysis connects tumor matrisome to immune response
    Su Bin Lim, Melvin L.K. Chua, Joe Poh-Sheng Yeong, Swee Jin Tan, Wan‐Teck Lim, Chwee Teck Lim · 2019 · npj Precision Oncology
  49. Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies
    Hongxing Shen, Eddy Shih-Hsin Yang, M. Conry, John B. Fiveash, Carlo M. Contreras, James A. Bonner, Lewis Z. Shi · 2019 · Genes & Diseases
  50. Identification of Distinct Immune Subtypes in Colorectal Cancer Based on the Stromal Compartment
    Rongfang Shen, Ping Li, Bing Li, Botao Zhang, Lin Feng, Shujun Cheng · 2020 · Frontiers in Oncology
  51. m6A regulator-mediated methylation modification patterns and characteristics of immunity and stemness in low-grade glioma
    Jianyang Du, Hang Ji, Shuai Ma, Jiaqi Jin, Shan Mi, Kuiyuan Hou, Jiawei Dong, Fang Wang, Chaochao Zhang, Yuan Li et al. · 2021 · Briefings in Bioinformatics
  52. Identification and quantification of immune infiltration landscape on therapy and prognosis in left- and right-sided colon cancer
    Junnan Guo, Du Chen, Shen-Hui Deng, Jia-Rong Huang, Jinxuan Song, Xiang-Yu Li, Binbin Cui, Yanlong Liu · 2021 · Cancer Immunology Immunotherapy
  53. The Predictive Value of Tumor Mutation Burden on Clinical Efficacy of Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Meta-Analysis
    Biao Ning, Yixin Liu, Miao Wang, Yi Li, Tianzi Xu, Yongchang Wei · 2022 · Frontiers in Pharmacology
  54. USP48 Stabilizes Gasdermin E to Promote Pyroptosis in Cancer
    Yidan Ren, Maoxiao Feng, Xiaodong Hao, Xiaoyan Liu, Juan Li, Peilong Li, Jie Gao, Qiuchen Qi, Lutao Du, Chuanxin Wang et al. · 2023 · Cancer Research
  55. An immune score reflecting pro- and anti-tumoural balance of tumour microenvironment has major prognostic impact and predicts immunotherapy response in solid cancers
    Artur Mezheyeuski, Max Backman, Johanna Sofia Margareta Mattsson, Alfonso Martín-Bernabé, Chatarina Larsson, Ina Hrynchyk, Klara Hammarström, Simon Ström, Joakim Ekström, Siarhei Mauchanski et al. · 2023 · EBioMedicine
  56. Regulation of Innate and Adaptive Antitumor Immunity by IAP Antagonists
    Stephanie K. Dougan, Michael Lawrence Dougan · 2018 · Immunotherapy
  57. Immunogenomic Analyses of Advanced Serous Ovarian Cancer Reveal Immune Score is a Strong Prognostic Factor and an Indicator of Chemosensitivity
    Dapeng Hao, Jie Liu, Meng Chen, Jingjing Li, Li Wang, Xiaobo Li, Qi Zhao, Lijun Di · 2018 · Clinical Cancer Research
  58. Biomarkers of response to immune checkpoint blockade in cancer treatment
    Takeo Fujii, Aung Naing, Christian D. Rolfo, Joud Hajjar · 2018 · Critical Reviews in Oncology/Hematology
  59. EZH2 Inhibition: A Promising Strategy to Prevent Cancer Immune Editing
    Ning Kang, Mark Eccleston, Pier‐Luc Clermont, Maryam Latarani, David Kingsley Male, Yuzhuo Z. Wang, Francesco Crea · 2020 · Epigenomics
  60. Therapeutic strategies to remodel immunologically cold tumors
    Minyu Wang, Sen Wang, Jayesh Desai, Joseph A. Trapani, Paul Joseph Neeson · 2020 · Clinical & Translational Immunology
  61. Multiomics analysis reveals a distinct response mechanism in multiple primary lung adenocarcinoma after neoadjuvant immunotherapy
    Chao Zhang, Kai Yin, SiYang Maggie Liu, Li‐Xu Yan, Jian Su, Yi-Long Lung Cancer Wu, Xu‐Chao Zhang, Wen‐Zhao Zhong, Xue-Ning Yang · 2021 · Journal for ImmunoTherapy of Cancer
  62. Integrated multiomics analysis and machine learning refine molecular subtypes and prognosis for muscle-invasive urothelial cancer
    Guangdi Chu, Xiaoyu Ji, Yonghua Wang, Haitao Niu · 2023 · Molecular Therapy — Nucleic Acids
  63. The future of affordable cancer immunotherapy
    Niels Schaft, Jan Dörrie, Gerold Schuler, Beatrice Schuler‐Thurner, Husam Sallam, Shiri Klein, Galit Eisenberg, Shoshana Frankenburg, Michal Lotem, Areej Khatib · 2023 · Frontiers in Immunology
  64. Inflammation-Induced Plasticity in Melanoma Therapy and Metastasis
    Michael Hölzel, Thomas Tüting · 2016 · Trends in Immunology
  65. TP53 Mutation as Potential Negative Predictor for Response of Anti-CTLA-4 Therapy in Metastatic Melanoma
    Wenjing Xiao, Nan Du, Taoyuan Huang, Jinan Guo, Xingkui Mo, Tao Yuan, Yong Chen, Ting Ye, C. Xu, Wenxian Wang et al. · 2018 · EBioMedicine
  66. Immune oncology, immune responsiveness and the theory of everything
    Tolga Turan, Deepti Kannan, Maulik R Patel, James Matthew Barnes, Sonia G. Tanlimco, Rongze Olivia. Lu, Kyle D. Halliwill, Sarah Kongpachith, Douglas E. Kline, Wouter Hendrickx et al. · 2018 · Journal for ImmunoTherapy of Cancer
  67. Distinct immune signatures in directly treated and distant tumors result from TLR adjuvants and focal ablation
    Michael Chavez, Matthew T. Silvestrini, Elizabeth S. Ingham, Brett Z. Fite, Lisa M. Mahakian, Sarah M. Tam, Asaf Ilovitsh, Arta Monir Monjazeb, William J. Murphy, Neil E. Hubbard et al. · 2018 · Theranostics
  68. Updates on Chronic HBV: Current Challenges and Future Goals
    Hannah M. Lee, Bubu A. Banini · 2019 · Current Treatment Options in Gastroenterology
  69. MITF controls the TCA cycle to modulate the melanoma hypoxia response
    Pakavarin Louphrasitthiphol, Ioanna Ledaki, Jagat Singh Chauhan, Paola Falletta, Robert Siddaway, Francesca Meteora Buffa, David Robert Mole, Tomoyoshi Soga, Colin R. Goding · 2019 · Pigment Cell & Melanoma Research
  70. A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma
    Amin H. Nassar, Kent William Mouw, Opeyemi A. Jegede, Atul Bhanudas Shinagare, Jaegil Kim, Chia‐Jen Liu, Mark M. Pomerantz, Lauren C. Harshman, Eliezer M. Van Allen, Xiao X. Wei et al. · 2019 · British Journal of Cancer
  71. News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors
    Ombretta Melaiu, Valeria Lucarini, Roberto Giovannoni, Doriana Fruci, Federica Gemignani · 2020 · Seminars in Cancer Biology
  72. Baseline Frequency of Inflammatory Cxcl9-Expressing Tumor-Associated Macrophages Predicts Response to Avelumab Treatment
    Yan Qu, Ji Wen, Graham D. Thomas, Wenjing Yang, Weiwei Prior, Wenqian He, Purnima Desai Sundar, Xiao Wang, Shobha Potluri, Shahram Salek‐Ardakani · 2020 · Cell Reports
  73. DEN-Induced Rat Model Reproduces Key Features of Human Hepatocellular Carcinoma
    Keerthi Kurma, Olivier Manches, Florent Chuffart, Nathalie Stürm, Khaldoun Gharzeddine, Jianhui Zhang, Marion Mercey-Ressejac, Sophie Rousseaux, Arnaud Millet, Hervé Lerat et al. · 2021 · Cancers
  74. Machine learning reveals diverse cell death patterns in lung adenocarcinoma prognosis and therapy
    Shun Wang, Ruohuang Wang, Dingtao Hu, Cao-Xu Zhang, Peng Cao, Jie Huang · 2024 · npj Precision Oncology
  75. Immune checkpoint inhibitors in colorectal cancer: limitation and challenges
    Suying Yan, Wanting Wang, Zhiqiang Feng, Jun Xue, Weizheng Liang, Xueliang Wu, Zhiquan Tan, Xipeng Zhang, Shuai Zhang, Xichuan Li et al. · 2024 · Frontiers in Immunology
  76. Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment
    Anselmo Papa, Davide Caruso, Martina Strudel, Federica Tomao, Federica Tomao · 2016 · Journal of Translational Medicine
  77. Dual reporter genetic mouse models of pancreatic cancer identify an epithelial‐to‐mesenchymal transition‐independent metastasis program
    Yang Chen, Valerie S. LeBleu, Julienne L. Carstens, Hikaru Sugimoto, Xiaofeng Zheng, Shruti Malasi, Dieter Saur, Raghu Kalluri · 2018 · EMBO Molecular Medicine
  78. Clinical and Genetic Tumor Characteristics of Responding and Non-Responding Patients to PD-1 Inhibition in Hepatocellular Carcinoma
    Stephan Spahn, Daniel Roessler, Radu Pompilia, Gisela Gabernet, Beryl Primrose Gladstone, Marius Horger, Saskia Biskup, Magdalena Feldhahn, Sven Nahnsen, Franz J. Hilke et al. · 2020 · Cancers
  79. Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis
    Hyun Ho Han, Yan Wang, Josué Curto, Sreeharsha Gurrapu, Sara Laudato, Alekya Rumandla, Goutam Chakraborty, Xiaobo Wang, Hong Chen, Yan Jiang et al. · 2022 · Cell Reports
  80. Harnessing epithelial-mesenchymal plasticity to boost cancer immunotherapy
    Yuanzhuo Gu, Zhengkui Zhang, Peter ten Dijke · 2023 · Cellular and Molecular Immunology
  81. Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer
    Won-Chul Lee, Lixia Diao, Jing Wang, Jianhua Zhang, Emily B. Roarty, Susan Varghese, Chi-Wan B. Chow, Junya Fujimoto, Carmen Behrens, Tina Cascone et al. · 2018 · Modern Pathology
  82. Tumor-Infiltrating Immunosuppressive Cells in Cancer-Cell Plasticity, Tumor Progression and Therapy Response
    Laura Lorenzo-Sanz, Purificacı́on Muñoz · 2019 · Cancer Microenvironment
  83. Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF -Mutant Melanoma
    Inês Pires da Silva, Kevin Y. X. Wang, James S. Wilmott, Jeff Holst, Matteo Salvatore Carlino, John Park, Camelia Y. J. Quek, Matthew J. Wongchenko, Yibing Yan, Graham J. Mann et al. · 2019 · Clinical Cancer Research
  84. Gain-of-Function Genetic Alterations of G9a Drive Oncogenesis
    Shinichiro Kato, Qing Yu Weng, Megan L. Insco, Kevin Y. Chen, Sathya Muralidhar, Joanna Poźniak, Joey Mark S. Diaz, Yotam Drier, Nathalie T. Nguyen, Jennifer A. Lo et al. · 2020 · Cancer Discovery
  85. DNA Repair Gene Mutations as Predictors of Immune Checkpoint Inhibitor Response beyond Tumor Mutation Burden
    David Hsiehchen, Antony Hsieh, Robert M. Samstein, Tianshi Lu, Muhammad Shaalan Beg, David E. Gerber, Tao Wang, Luc G.T. Morris, Hao Zhu · 2020 · Cell Reports Medicine
  86. A pan-cancer transcriptome analysis of exitron splicing identifies novel cancer driver genes and neoepitopes
    Ting-You Wang, Qi Liu, Yanan Ren, Sk. Kayum Alam, Li Wang, Zhu Zhu, Luke H. Hoeppner, Scott M. Dehm, Qi Cao, Rendong Yang · 2021 · Molecular Cell
  87. MRTF-A-NF-κB/p65 axis-mediated PDL1 transcription and expression contributes to immune evasion of non-small-cell lung cancer via TGF-β
    Fu Du, Xin Qi, Aotong Zhang, Fanfan Sui, Xuemin Wang, Christopher G. Proud, Cunzhi Lin, Xinglong Fan, Jing Li · 2021 · Experimental & Molecular Medicine
  88. Polyamine Immunometabolism: Central Regulators of Inflammation, Cancer and Autoimmunity
    Tzu-Yi Chia, Andrew Zolp, Jason M. Miska · 2022 · Cells
  89. Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette–Guérin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma
    Jessica Da Gama Duarte, Sagun Parakh, Miles Cameron Andrews, Katherine Woods, Anupama Pasam, Candani S. A. Tutuka, Simone Ostrouska, Jonathan Michael Blackburn, Andreas Behren, Jonathan Simon Cebon · 2018 · Frontiers in Immunology
  90. Trial watch: immune checkpoint blockers for cancer therapy
    Vanpouille-Box, Claire, Lhuillier, Claire, Bezu, Lucillia, Aranda, Fernando, Yamazaki, Takahiro, Kepp, Oliver, Fucikova, Jitka, Spisek, Radek, Demaria, Sandra, Formenti, Silvia C. et al. · 2017 · OncoImmunology
  91. Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response
    Julie E. Stein, A. Soni, Ludmila Danilova, Tricia R. Cottrell, Thomas Frank Gajewski, Frank Stephen Hodi, Shailender Bhatia, Walter John Urba, William Howard Sharfman, Megan Wind‐Rotolo et al. · 2019 · Annals of Oncology
  92. Prediction of biomarkers and therapeutic combinations for anti-PD-1 immunotherapy using the global gene network association
    Chia-Chin Wu, Yanru Wang, John Andrew Livingston, Jianhua Zhang, P. Andrew Futreal · 2022 · Nature Communications
  93. The roles of TGF-β and VEGF pathways in the suppression of antitumor immunity in melanoma and other solid tumors
    Melissa Tian Bu, Pallavi Chandrasekhar, Lizhong Ding, Willy Hugo · 2022 · Pharmacology & Therapeutics
  94. Distinct Mechanisms of Mismatch Repair Deficiency Delineate Two Modes of Response to PD-1 Immunotherapy in Endometrial Carcinoma
    Ryan Dz-Wei Chow, Tai Michaels, Stefania Bellone, Tobias M.P. Hartwich, Elena Bonazzoli, Akiko Iwasaki, Eric Song, Alessandro Davide Santin · 2022 · Cancer Discovery
  95. Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic Latency
    Fang Zhao, Antje Sucker, Susanne Horn, Christina Heeke, Nicola Bielefeld, Barbara Schrörs, Anne Bicker, Monika Lindemann, Alexander Roesch, Gustav Gaudernack et al. · 2016 · Cancer Research
  96. Molecular Pathways: Oncologic Pathways and Their Role in T-cell Exclusion and Immune Evasion—A New Role for the AXL Receptor Tyrosine Kinase
    Todd Anthony Aguilera, Amato J. Giaccia · 2017 · Clinical Cancer Research
  97. Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma
    Pok Fai Wong, Wei Wei, Swati Gupta, James William Smithy, Daniel A. Zelterman, Harriet M. Kluger, David L. Rimm · 2019 · Journal for ImmunoTherapy of Cancer
  98. A Serum Protein Signature Associated with Outcome after Anti–PD-1 Therapy in Metastatic Melanoma
    Jeffrey S. Weber, Mario Sznol, Ryan Joseph Sullivan, Shauna M. Blackmon, Genevieve Marie Boland, Harriet M. Kluger, Ruth Halaban, Antonietta Bacchiocchi, Paolo A. Ascierto, Mariaelena Capone et al. · 2017 · Cancer Immunology Research
  99. Targeting cancer stem cells in the clinic: Current status and perspectives
    Stephanie Annett, Tracy Robson · 2018 · Pharmacology & Therapeutics
  100. Remodeling the Tumor Microenvironment Sensitizes Breast Tumors to Anti-Programmed Death-Ligand 1 Immunotherapy
    Renee Clift, Jennifer Souratha, Sheryl A. Garrovillo, Susan J. Zimmerman, Barbara Blouw · 2019 · Cancer Research